References
- Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009; 333:43-82; PMID:19768400
- McMenamin J, Andrews N, Robertson C, Fleming D, Durnall H, von Wissmann B, Ellis J, Lackenby A, Cottrell S, Smyth B, Zambon M, Moore C, Watson JM, Pebody RG. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill 2013; 18; PMID: 23399421
- World Health Organization. Influenza vaccines–WHO position paper. Wkly Epidemiol Rec 2005; 80:279-87; PMID:16171031
- Chen J, Deng YM. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J 2009; 6:30; PMID:19284639; http://dx.doi.org/10.1186/1743-422X-6-30
- World Health Organization. Summary of the 2012-2013 influenza season in the WHO European Region. Geneva: World Health Organization; 2013. Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/195824/Summary-of-the-20122013-influenza-season-in-the-WHO-European-Region-final.pdf
- World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season. Wkly Epidemiol Rec 2012; 87:83-95; PMID:22462202
- World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season. Wkly Epidemiol Rec 2013; 88:101-14; PMID:23544236
- Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, Robertson C, Cottrell S, Smyth B, Zambon M, Moore C, Fleming DM, Watson KM. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2012; 18; PMID: 23399424
- Cramer J, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard G. Influenza A (H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. Euro Surveill 2012; 17; PMID: 22264864
- Global Influenza Surveillance and Response System (GISRS). Influenza virus activity in the world. Geneva: World Health Organization 2013. Available from: http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport_20131209/en/
- Robert Koch Institute. Recommendations of the standing commitee on vaccination (STIKO) at the Robert Koch-Institute / effective: august 2013. Epidemiologisches Bulletin 2013; 34.
- Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theess W, Burchard GD, Cramer JP. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu): an open label, uncontrolled study. Hum Vaccin Immunother 2013; 10; PMID:24240428
- Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PLoS One 2013; 8:e70866; PMID:23976960; http://dx.doi.org/10.1371/journal.pone.0070866
- Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Borso D, Frimmel S, Riebold D, Reisinger EC. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. Vaccine 2010; 29:1228-34; PMID:21167116; http://dx.doi.org/10.1016/j.vaccine.2010.11.092
- Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994; 32:2468-73; PMID:7814484